Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.

based drugs, no observational study has investigated this association in the real world setting What this study adds Use of DPP-4 inhibitors was associated with a near doubling of the risk of cholangiocarcinoma An association of similar magnitude was observed with GLP-1 receptor agonists, but this did not reach statistical significance Incretin based drugs therefore might be associated with an increased risk of cholangiocarcinoma in people with type 2 diabetes Acknowledgments We thank the Uppsala Monitoring Centre and the National Pharmacovigilance Centers for providing the pharmacovigilance data for the present study.

also in 111,027 other papers